China approves Vifor's iron deficiency IV infusion
Ferinject, an intravenous (IV) infusion for the treatment of iron deficiency, has won Chinese approval, increasing its global lead over Monofer, which is marketed by Pharmacosmos in Europe.
by albert rønning-andersson, translated by daniel pedersen
On Monday, Chinese health authorities approved CSL Vifor’s Ferinject as an intravenous (IV) infusion for the treatment of iron deficiency, a company press released announced.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Pharmacosmos expects massive growth in four years
For subscribers
